Background: This study evaluated the results of thoracic metastasectomy for germ cell tumours to assess long term survival and identify prognostic factors.
Introduction
Testicular cancer is the most common neoplasm in males under the age of 40 [1] . It constitutes about 2% of all malignancies, and about 95% of all testicular tumour are of germ cell origin (GCT) [2] . The incidence of testicular cancer varies significantly according to the geographic area [3] , but it has been rising everywhere during this century and has almost doubled over the last two decades [4] .
In the last 30 years, the use of cisplatin-based, combination chemotherapy has dramatically improved the chances of cure of these neoplasms, rising from around 10% in the 1960s up to the current rate of 85%-90% [2, 4] .
The monitoring of response to treatment has been further aided by the development of tumour markers, which reflect with high sensitivity any change in body tumour burden.
Because of their high sensitivity to chemotherapy and radiotherapy, GCT have been characterised by Einhorn in 1981 as a model of a curable neoplasm [5] . However, approximately 20% of patients presenting with metastatic disease will die of tumour refractory to initial chemotherapy or from recurrent disease after an initial complete response [1] . At the time of diagnosis it has been estimated that pulmonary metastases are present in 50% of patients with retroperitoneal involvement and in 10% of patients without retroperitoneal extension [6] . After completion of primary treatment, bulky disease remains in up to 50% of such cases [7] and the residual mass may contain viable malignancy, mature teratoma or merely fibrosis and/or necrosis [4] .
The main therapeutic purpose of post chemotherapy surgical resection is to remove residual mature teratoma, which may be the origin of late recurrence by malignant dedifferentiation or cause concern later as 'growing teratoma' [8] [9] [10] [11] . Furthermore, histological examination identifies those patients who do not need further treatment as the residual disease has been radically resected and shown to contain only completely necrotic or fibrotic masses or mature teratoma [8] . In addition, those patients shown to have residual malignancy within the resected masses have not been cured and need additional chemotherapy.
Residual deposits consisting of cystic and fully differentiated tumour are found in 22%-44% of cases and may either relapse after several years of stability or enlarge causing pressure symptoms [11] .
However there is no general agreement as to whether all residual masses detected after chemotherapy should be resected, as only a small proportion of resected specimens (15%-25%) contain viable cancer cells [12, 13] and surgery would not be beneficial in patients with only fibrosis or necrosis in the resected specimen [8] . This paper reports our experience in the management of thoracic metastases from GCT with the aim of clarifying the role of adjunctive surgery in relation to the nature and extent of intrathoracic residual disease.
Patients and methods
From January 1980 to May 1997, 171 consecutive patients underwent thoracic metastasectomy for germ cells tumour at Royal Brompton Hospital. Patients with mediastinal or hilar node metastases were added to those previously included in the International Registry of Lung Metastases data base [14] and a new set of information specific for germ cell tumours were collected.
All pathological data concerning primary tumour and pathological results of metastasectomies were classified according to the British Testicular Tumours Panel [15] . Among the various staging systems current in use, we utilised the Royal Marsden Hospital staging classification [16] .
The accrual of patients for this retrospective study began after the introduction of cisplatin as a chemotherapeutic agent by the Testicular Tumour Unit at the Royal Marsden Hospital.
Of the 171 cases so identified, 30 were excluded because crucial clinical information was unavailable. Among the 141 evaluated patients, thoracic metastases were present at time of diagnosis in 102 patients presenting with the primary tumour and were the presenting feature in two other patients. Thoracic metastases developed following first line treatment in 37 patients (after a disease-free interval of one to 12 months in 10 patients, more than one year in 27 patients with a median disease free interval of 12 months). Table 1 summarises the main features of the 141 patients eligible for the present analysis. The histological subtypes of the primary tumours.
were malignant intermediate teratoma (MTI) in 50 (35%), malignant undifferentiated teratoma (MTU) in 49 (34%), teratoma non otherwise specified in 12 (8%), differentiated teratoma (TD) in 11 (7.6%), malignant trophoblastic teratoma (MTT) in 11 (7.6%), yolk sac tumour (YST) in five (3%) and pure seminoma in three (2%) patients. Mixed tumour were present in 30 patients (20%).
The mean age, at time of metastasectomy, was 29.2 (range 16-58 years). The primary site was testis in 97% of the patients; one patient having a retroperitoneal primary and another an unknown primary site. The stage at presentation was as follows: 18 (13%) stage 1,18 (13%) stage II, 15 (10%) stage III, and 90 (63%) stage IV. Of the 141 patients who eventually came to thoracic metastasectomy, 72 (51%) had extrathoracic metastases at time of primary presentation; 68 (87%) of these had retroperitoneal node deposits, eight had involved superficial lymph nodes and one had a bone metastases. Four patients presented with concurrent involvement of retroperitoneal and superficial lymph node.
Alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) at presentation were available in 111 and 112 patients respectively. Ten patients belonged to the high risk group according to the final report of the International Germ Cell Cancer Collaborative Group (IGCCCG) [17] .
A total of 123 (87%) of patients received chemotherapy in addition to surgery to the primary site, the regimen utilised was cisplatinbleomicin-etoposide (BEP) in 52 patients, cisplatin-vinblastin-bleomicin (PVB) in 21 and other type of treatment in 50 patients.
Statistical analysis
Survival was calculated from the time of the first thoracic metastasectomy to the last date of follow up by means of SPSS life table procedure. Survival curves were estimated by the Kaplan-Meier method and differences were analysed using the log-rank test. We utilised a Cox regression model with backward and forward selection to identify the variables best related to survival and to exclude those which did not predict survival.
Results

Surgical resection
The main surgical features are shown in Table 2 . At time of first thoracic metastasectomy 73 (51%) patients had thoracic metastases localised in the lung only, 34 (24%) had metastases in the lung and mediastinum and 34 (24%) in the mediastinum only.
Unilateral thoracotomy was the most frequently used surgical approach (52%), followed by thoraco-laparotomy (18%), sternotomy (17%), staged lateral thoracotomies (11%), and bilateral synchronous thoracotomies (2%). One patient had a solitary lung metastasis removed by a video-thoracoscopic approach. Patients who underwent surgery by a planned, sequential or staged thoracotomy were considered to have had a first-time metastasectomy operation, and were not classified as having redo surgery.
Forty-four patients had a single lesion resected, 48 patients had two or three lesions and 49 had more than three lesions resected. Local excision were the most frequent resection procedures (62%), followed by lobectomy (11%), anatomic segmentectomy (2%), and pneumonectomy (2%).
Among patients with mediastinal disease at time of first metastasectomy, five cases had infiltration of the vagus or phrenic nerve, four patients had the superior vena caval syndrome and three patients had massive tracheal compression. Extended resections were performed to include the thymus in six patients, pericardium in two, chest wall in one, and myocardium through cardiopulmonary bypass in two patients [18] . The removal of posterior mediastinal metastases in the retrocrural area was associated with thoracic duct resection in three cases and in 15 patients with retroperitoneal lynphadenectomy which required splenectomy in one patient and nephrectomy in another patient.
At the time of first metastasectomy, complete resection was possible in 123 patients (87%). Eighteen (13%) patients had an incomplete resection, 14 with macroscopic residual disease and four with microscopic residual disease. There were two perioperative deaths from all causes within 31 days (2%).
Pathological features
Pathological findings after the first metastasectomy are summarised in Table 3 : 23% of patients had a complete regression to necrosis or fibrosis, 45% had only differentiated teratoma, and malignant viable cells were found in 32%.
The frequency of hilar nodes metastases was only 11% (16 of 141) overall and 15% (16 of 107) among patients with lung metastases. There was no difference according to the pathology of the pulmonary deposits (NF, TD or malignant teratomatous elements).
Among the 14 patients with macroscopic evidence of residual disease after the metastasectomy seven had his- Abbreviations: see Table 3 . * Including two perioperative deaths. tological evidence of viable malignancy and seven had necrosis/fibrosis or differentiated teratoma.
Neither AFP nor HCG status at the time of metastasectomy were predictive of the pathological findings after metastasectomy, as persisting malignant disease was detected in 23% (24 of 102) of patients with negative markers.
Recurrence
The overall recurrence rate after first metastasectomy was 47% (67 of 141 patients). As shown in Table 4 ; in 34 patients the recurrence was intrathoracic, in 20 intra and extrathoracic and in 13 was extrathoracic only. The overall median time to recurrence was 7.3 months (mean 20 months, range 1-190 months).
The probability of relapse was 72% (33 of 46) for patients with viable malignant cells in the resected specimen, 38% (24 of 63) for patients with differentiated teratoma and 31% (10 of 32) for patients with necrosis and fibrosis. The overall recurrence rate in the group of patients with NForTD was surprisingly high (36%).
Among the 46 patients with malignant viable cells in the metastasectomy specimen, the median time to recurrence was 5.2 months (range , and 48% (16 of 33) of relapses were intrathoracic, 33% (11 of 33) intra and extrathoracic and 18% (six of 33) extrathoracic only.
Of the 67 patients with recurrence after the first thoracic metastasectomy there were 27 deaths, 63% of these in the group shown to have residual malignant tissue and 37% in the group of patients whose metastases contained only TD or NF.
A second thoracic metastasectomy was performed in 30 patients, 14 of which presented with the second recurrence in the lung only, 12 had combined lung and mediastinal recurrence and four patients had mediastinal recurrence only. Four patients had an incomplete resection and the overall recurrence rate was 42%. Eight patients had three metastasectomy operation, two patients had four and one patient had five. The total number of metastasectomies performed on the whole series was 182.
The proportion of patients who underwent a second thoracic metastasectomy was higher in the group with necrosis and fibrosis or differentiated teratoma 64% (20 of 30), than in the group of patients with malignant viable cells 33% (10 of 30). Of interest, at second metastasectomy six out of 20 patients found to have benign disease at the initial metastasectomy had malignant tumour in the resected recurrence.
Survival
The mean follow up was 65.7 months (median 44.5 months) with a range of 0.1-216 months. The corresponding values were 80 months (median 67 months) for patients with necrosis and fibrosis and 43 months (median 23 months) for patients with viable malignant cells. The median follow-up time for surviving patients was 44 months. The crude mortality rate was 19% (27 of 141); only four patients were lost to follow-up, one patient died for causes unrelated to the disease.
The survival of patients with thoracic metastases at the time of primary tumour presentation was slightly better than survival of patients who developed thoracic metastases following first line treatment, but the difference did not reach statistical significance.
Overall actuarial survival following the first pulmonary metastasectomy operation was 78% at five years, 76 at 10 years and 66% at 15 years. Table 5 shows the cumulative proportion of survivors at five and ten years in relation to main clinical feature of their primary tumours and thoracic metastases.
Of the several variables considered, a few reached a statistical significance on univariate analysis: pathology of resected specimens (P = 0.0001), residual disease at time of metastasectomy (P -0.019) and number of resected metastases (P = 0.0011). Figure 1 illustrates the overall actuarial survival up to 15 years (180 months) according to the pathological result at metastasectomy (P -0.0001). Patients with a complete regression to necrosis or fibrosis had a far Table 3 a For 37 patients with thoracic recurrence after prior CR. Figure 1 . Overall actuarial survival in the whole series (n = 141) according to the pathological result of thoracic metastasectomy. Patients with a complete regression to necrosis and fibrosis (NF; n = 32) had a far better survival (95% at 15 years) compared with patients with malignant teratomatous elements (MTE; n = 46) in the resected specimen (53% at 15 years). The survival of patients with differentiated teratoma (TD; n = 63) in the resected specimen was 67% at 15 years.
MTE
better survival (95%, 10 years) compared with patients with viable malignancy (53%, 10 years). The survival of patients with differentiated teratoma in the resected specimen was 87% at five, 85% at 10, and 67% at 15 years.
Patients with MTI and MTU in the resected specimen had a similar survival (58% at five and 10 years for MTI group and 53% at five years and ten years for MTU complete resection k>g-rank p».O5 residual disease Figure 2 . Actuarial survival in the subset of patients (n = 46) with viable malignant cells in the resected specimen at the time of the first thoracic metastasectomy according to the completeness of resection. The survival after complete metastasectomy was 60% at 15 years. The corresponding value for incomplete resection was 27% (P = 0.05). group). The six patients with MTT had the worst result with 20% survival at five and 10 years. In the subset of patients with viable malignant cells at the time of first metastasectomy, several features were analysed to study which best predicted survival. The survival after radical surgery was 60% at 10 and 15 years; 10 patients were alive at five years and one at 10 years. The corresponding survival rates for incompletely resected patients were 27% at five and 10 years with a median of 18 months (P = 0.05, Figure 2 ). In the latter group there was only one patient still alive after three years. In this subset of patients with viable tumor cells also the number and site of thoracic metastases had some impact on survival. In fact, the five-year survival was 68% for patients with solitary lesions and 33% for multiple lesions (Figure 3 , P = 0.06), and 88% for those with mediastinal metastases only, versus 42% for those with lung metastases with and without mediastinal deposits (Figure 4 , P = 0.04). On the other hand neither the disease-free interval nor the presence of retroperitoneal or other extrathoracic metastases influenced survival (P -0.9 and P = 0.5, respectively).
Patients who underwent a single thoracic metastasectomy were plotted against patients who underwent two or more thoracic metastasectomy (data not shown). In the first group of patients the five-and 10-year survival is 48% with a median of 57 months, in the second group the five-and 10-year survival is 66% (P = 0.17). Whilst these data are clearly affected by patients selection, as a patient needed to survive and have limited disease in order to be eligible for further surgery, they indicate that repeat metastasectomy, whenever applicable, carries the same chance of success as the first operation.
Statistical analysis of prognostic factors
Of the several clinical features entered in the multivariate analysis, the pathological findings after metastasectomy, the completeness of surgical resection and the number of resected metastases were the factors that significantly correlated with survival. The presence of malignant disease in the resected specimen was associated with a 5.7 times relative risk of death (coefficient 1.7, standard error 0.42, P -0.0000) and residual disease at resection was associated with 4.0 times relative risk of death (coefficient 1.3, standard error 0.4, P = 0.0041). Patients with multiple metastases resected had a 4.1 times relative risk of death (coefficient 1.4, standard error 0.4, P -0.0014).
Whilst at univariate analysis (log-rank test) the site of disease (pulmonary versus mediastinal only) achieved statistically significance, this prognostic value was not confirmed by the Cox model (P = 0.32).
In addition, multivariate analysis revealed a 3.2 times higher risk of relapse in patients with malignant teratomatous elements at the time of thoracic metastasectomy (coefficient 1.1, standard error 0.5, P = 0.03).
Discussion
The development of effective chemotherapy in the late seventies, together with a multidisciplinary management, has lead to a dramatic improvement in the dismal prognosis of patients with disseminated germ cell tumours [19] . Concurrent surgical reports showed the value of More recently, the International Registry of Lung Metastases, by reviewing the long term results of a large cohort of cases, confirmed that surgical resection of lung metastases from germ cell tumours had a far better survival (over 60% at 10 years) compare to epithelial tumours or sarcomas [12] . In addition, this analysis revealed that well-established prognostic factors after lung metastasectomy for other malignancies, such as disease free interval or number of lesions, did not predict the outcome of germ cell tumours.
The present study was based on a 17-year surgical experience of Royal Brompton Hospital in co-operation with the Testicular Tumour Unit of Royal Marsden Hospital, and provided comprehensive surgical and pathological data of 182 metastasectomy operations performed on 141 patients, previously treated with cisplatin based chemotherapy.
Our data have revealed a high frequency of malignant disease (32%) at thoracic metastasectomy, 22% showing complete regression to necrosis/fibrosis (NF) and 45% transformation to mature teratoma (TD). Despite such a high rate of residual malignancy, macroscopic and microscopic complete resection was achieved in a large proportion of all cases (87%), and in 80% of those with malignant metastases. None of the clinical features investigated could accurately predict the ultimate pathological results.
We separately analysed the results of surgery in the group of patients with thoracic metastases at presentation (n = 104) and in those with thoracic first recurrence (n = 37); there were no significative differences concerning the patients features, the pathological result of thoracic metastasectomy and the outcome in the two subsets. In particular, the frequency of malignant lesions (Table 3 ) and survival after surgical resection ( Figure 5 , P = 0.8) were similar in the two groups of patients.
When the outcome of thoracic metastasectomy was assessed by univariate analysis, the long term survival was higher in those cases in which only either necrosis/ fibrosis or mature teratomatous elements were presents, but was still reasonably good in patients bearing malignant foci within the resected specimen, thus supporting the curative role of thoracic metastasectomy. In the subset of 46 malignant metatases, there was a trend toward better survival for solitary metastases and those patients with only mediastinal disease.
In our experience, the majority (79%) of relapses after metastasectomy involved the chest again. Whilst the chance of failure at any site was higher for malignant deposits (72%), over one third (34 of 95) of patients with TD or N/F failed after metastasectomy. The chance of surgical rescue was however higher for the group of patients with necrosis/fibrosis or mature elements at first metastasectomy (58% versus 30% for malignant disease).
Multivariate analysis pointed out three independent risk factors for long term survival: pathology of resected metastases, completeness of resection and the number of resected metastases The overall risk of death was nearly six times higher for patients with malignant disease in the resected specimens, and 4.0 times higher for patients with incomplete resection and 4.1 higher for patients with multiple metastases.
In conclusion, our data strongly support the value of thoracic metastasectomy to asses pathological response and achieve permanent cure of chemoresistant disease. The long term results achieved in patients with malignant deposits justify the attempt of radical surgical excision, that may be technically challenging and require repeated or staged procedures. The critical choice of approach and the timing of salvage surgery, in the framework of optimal medical treatment, emphasises the importance of continued multidisciplinary approach in germ cell tumours.
